Search Results - "Knoebl, Paul"

Redefining outcomes in immune TTP: an international working group consensus report by Cuker, Adam, Cataland, Spero R., Coppo, Paul, de la Rubia, Javier, Friedman, Kenneth D., George, James N., Knoebl, Paul N., Kremer Hovinga, Johanna A., Lӓmmle, Bernhard, Matsumoto, Masanori, Pavenski, Katerina, Peyvandi, Flora, Sakai, Kazuya, Sarode, Ravi, Thomas, Mari R., Tomiyama, Yoshiaki, Veyradier, Agnès, Westwood, John-Paul, Scully, Marie

“…Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency…”
Get full text

Emicizumab for the treatment of acquired hemophilia A by Knoebl, Paul, Thaler, Johannes, Jilma, Petra, Quehenberger, Peter, Gleixner, Karoline, Sperr, Wolfgang R.

“…Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment,…”
Get full text

International recommendations on the diagnosis and treatment of acquired hemophilia A by Tiede, Andreas, Collins, Peter, Knoebl, Paul, Teitel, Jerome, Kessler, Craig, Shima, Midori, Di Minno, Giovanni, d'Oiron, Roseline, Salaj, Peter, Jiménez-Yuste, Victor, Huth-Kühne, Angela, Giangrande, Paul

“…Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII), occurs in both men and…”
Get full text

Acquired hemophilia A: Updated review of evidence and treatment guidance by Kruse‐Jarres, Rebecca, Kempton, Christine L., Baudo, Francesco, Collins, Peter W., Knoebl, Paul, Leissinger, Cindy A., Tiede, Andreas, Kessler, Craig M.

“…Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors) against endogenous factor VIII (FVIII) that leads to bleeding, which…”
Get full text

Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia by Thaler, Johannes, Jilma, Petra, Samadi, Nazanin, Roitner, Florian, Mikušková, Eva, Kudrnovsky-Moser, Stephan, Rettl, Joachim, Preiss, Raphael, Quehenberger, Peter, Pabinger, Ingrid, Knoebl, Paul, Ay, Cihan

“…Cases of ChAdOx1 nCoV-19 (AstraZeneca) vaccinated patients with thrombocytopenia, elevated D-dimer, and elevated platelet factor 4 (PF4) antibody levels with-…”
Get full text

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis by Peyvandi, Flora, Cataland, Spero, Scully, Marie, Coppo, Paul, Knoebl, Paul, Kremer Hovinga, Johanna A., Metjian, Ara, de la Rubia, Javier, Pavenski, Katerina, Minkue Mi Edou, Jessica, De Winter, Hilde, Callewaert, Filip

“…The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and…”
Get full text

The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vector‐based COVID‐19 vaccination: Where there is much light, the shadow is deep by Thaler, Johannes, Ay, Cihan, Knoebl, Paul

“…During the following weeks and months, further clinical and experimental data were published at an impressive pace, setting the ground for evidence-based…”
Get full text

Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study by Tran, Huyen, von Mackensen, Sylvia, Abraham, Aby, Castaman, Giancarlo, Hampton, Kingsley, Knoebl, Paul, Linari, Silvia, Odgaard-Jensen, Jan, Neergaard, Jesper Skov, Stasyshyn, Oleksandra, Thaung Zaw, Jay Jay, Zulfikar, Bulent, Shapiro, Amy

“…Patient-reported outcomes (PROs) reflect patient perceptions of disease and treatment and are important for evaluating new therapies. Evaluate the effects of…”
Get full text

Safer steps on a narrow path by Knoebl, Paul

Get full text

INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA by Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Filip Callewaert, Hilde De Winter

“…Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired…”
Get full text

Is there an association between hemostatic abnormalities and the outcome of acute lung injury? by Knoebl, Paul N

Get full text

Severe congenital protein C deficiency : the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications by Knoebl, Paul N

“…Summarizes the current knowledge on protein C replacement therapy in congenital protein C deficiency. Source: National Library of New Zealand Te Puna…”
Get full text

Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A by Knöbl, Paul

“…Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies inhibiting the function of coagulation factor VIII. It is characterized by…”
Get full text

Is It HIT? by Knoebl, Paul

Get full text

Should emicizumab be used in patients with acquired hemophilia A? by Tiede, Andreas, Kemkes-Matthes, Bettina, Knöbl, Paul

“…Emicizumab is currently approved to prevent bleeding in patients with congenital hemophilia A with or without neutralizing antibodies (inhibitors) against…”
Get full text

Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults by Knöbl, Paul

“…Thrombotic thrombocytopenic purpura (TTP) is a clearly defined entity of thrombotic microangiopathies (TMAs), a heterogeneous group of disorders characterized…”
Get more information

Thrombotic thrombocytopenic purpura by Knöbl, Paul

“…Summary Thrombotic thrombocytopenic purpura (TTP) is a clearly defined entity of the thrombotic microangiopathies (TMA), a heterogeneous group of disorders…”
Get full text

Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis by Gelbenegger, Georg, Traby, Ludwig, Rahimi, Nina, Knöbl, Paul

“…Acquired haemophilia A (AHA) is an autoimmune bleeding disorder caused by autoantibodies blocking coagulation factor VIII (FVIII). Haemostatic management of…”
Get full text

Acquired haemophilia: an overview for clinical practice by Kessler, Craig M., Knöbl, Paul

“…Acquired haemophilia is a potentially life‐threatening bleeding disorder caused by the development of autoantibodies against coagulation factors, most commonly…”
Get full text

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study by Holstein, Katharina, Liu, Xiaofei, Smith, Andrea, Knöbl, Paul, Klamroth, Robert, Geisen, Ulrich, Eichler, Hermann, Miesbach, Wolfgang, Tiede, Andreas

“…Acquired hemophilia A (AHA) is due to autoantibodies against coagulation factor VIII (FVIII) and most often presents with unexpected bleeding. In contrast to…”
Get full text